세계의 부신 위기 관리 시장 예측(-2032년) : 치료 종류별, 투여 경로별, 환자층별, 유통 채널별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Adrenal Crisis Management Market is accounted for $2.6 billion in 2025 and is expected to reach $4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.

According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.

Market Dynamics:

Driver:

Rising prevalence of autoimmune disorders

The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.

Restraint:

High cost of treatment

Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.

Opportunity:

Digital health solutions for patient monitoring and adherence

Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.

Threat:

Reimbursement hurdles for newer products and kits

Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.

The glucocorticoid therapy segment is expected to be the largest during the forecast period

The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors, catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.

The paediatrics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.

Key players in the market

Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.

Key Developments:

In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai(TM) novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE(R), a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO(R) hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Treatment Types Covered:

• Glucocorticoid Therapy
• Mineralocorticoid Therapy (Fludrocortisone)
• Fluid & Electrolyte Replacement Therapy
• Adjunctive Therapies

Route of Administrations:

• Intravenous (IV)
• Intramuscular (IM)
• Oral
• Subcutaneous

Patient Groups Covered:

• Adults
• Pediatrics
• Geriatrics
• Neonates

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Drug Distributors

End Users Covered:

• Hospitals
• Emergency Care Centers
• Specialty Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Adrenal Crisis Management Market, By Treatment Type

• 5.1 Introduction
• 5.2 Glucocorticoid Therapy
  • 5.2.1 Hydrocortisone (IV/IM)
  • 5.2.2 Dexamethasone
  • 5.2.3 Other Glucocorticoids
• 5.3 Mineralocorticoid Therapy (Fludrocortisone)
• 5.4 Fluid & Electrolyte Replacement Therapy
• 5.5 Adjunctive Therapies

6 Global Adrenal Crisis Management Market, By Route of Administration

• 6.1 Introduction
• 6.2 Intravenous (IV)
• 6.3 Intramuscular (IM)
• 6.4 Oral
• 6.5 Subcutaneous

7 Global Adrenal Crisis Management Market, By Patient Group

• 7.1 Introduction
• 7.2 Adults
• 7.3 Pediatrics
• 7.4 Geriatrics
• 7.5 Neonates

8 Global Adrenal Crisis Management Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Specialty Drug Distributors

9 Global Adrenal Crisis Management Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Emergency Care Centers
• 9.4 Specialty Clinics
• 9.5 Home Care Settings
• 9.6 Ambulatory Surgical Centers
• 9.7 Other End Users

10 Global Adrenal Crisis Management Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Eton Pharmaceuticals
• 12.2 Takeda Pharmaceutical Company Limited
• 12.3 Pfizer Inc.
• 12.4 Antares Pharma
• 12.5 Sandoz International GmbH
• 12.6 Halozyme Therapeutics
• 12.7 Novartis AG
• 12.8 Teva Pharmaceutical Industries Ltd.
• 12.9 GlaxoSmithKline plc
• 12.10 AbbVie Inc.
• 12.11 Mylan N.V.
• 12.12 Ferring Pharmaceuticals
• 12.13 Hikma Pharmaceuticals
• 12.14 Sun Pharmaceutical Industries Ltd.
• 12.15 Cipla Ltd.
• 12.16 Sanofi S.A.
• 12.17 Bayer AG
• 12.18 AstraZeneca plc
• 12.19 Amneal Pharmaceuticals
• 12.20 Endo International plc